Online Exclusive
07/14/2021
The agency’s request for a review of the approvals process for the monoclonal antibody aducanumab is the latest twist in an unprecedented saga involving the Alzheimer disease treatment. We asked a panel of experts to analyze the approvals...
The agency’s request for a review of the approvals process for the monoclonal antibody aducanumab is the latest twist in an unprecedented saga involving the Alzheimer disease treatment. We asked a panel of experts to analyze the approvals...
The agency’s request for a...
07/14/2021
First Report Managed Care